Treatment of Chronic Obstructive Pulmonary Disease (COPD) With Pulmonary Diffusion Dysfunction by REGEND001
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide
with the characterization of obstructed airflow. In a large number of patients, diffusion
function is impaired along with the progression of disease. REGEND001 Autologous Therapy
Product, made from bronchial basal cells with ability to regenerate lung tissue, is promising
to COPD treatment. In this study, a multicenter, randomized, single-blind,
placebo-parallel-controlled trial is performed to assess the efficacy and safety of REGEND001
Autologous Therapy Product in treatment of chronic obstructive pulmonary disease with
pulmonary diffusion dysfunction.
Phase:
Phase 2
Details
Lead Sponsor:
Regend Therapeutics
Collaborators:
China-Japan Friendship Hospital Regend Therapeutics XLotus (Jiangxi) Co, Ltd. Ruijin Hospital Shanghai East Hospital Shanghai Zhongshan Hospital Southwest Hospital, China The First Affiliated Hospital of Guangzhou Medical University